ZEPATIER® (elbasvir és grazoprevir)

 1.  ZEPATIER alkalmazási előírás

 2. Clark VC, Peter JA, Nelson DR. New therapeutic strategies in HCV: second generation protease inhibitors.
Liver Int. 2013;33(suppl 1):80–84. doi:10.1111/liv.12061.

 3. ZEPATIER European Public Assessment Report, EMA/377766/2016

 4. European Association for the Study of Liver. EASL Recommendations on Treatment of Hepatitis
C 2016. J Hepatol. 2016; http://dx.doi.org/10.1016/j.jhep.2016.09.001.

 5. Jacobson IM, Lawitz E, Kwo PY, et al. An integrated analysis of 402 compensated cirrhotic patients with HCV genotype (GT) 1, 4 or 6 infection treated with grazoprevir/elbasvir [AASLD abstract 42]. Hepatology. 2015;62(suppl):229A.

 6. Zeuzem S, Ghalib R, Reddy KR, et al. Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic HCV genotype 1, 4, or 6 infection. Ann Intern Med. 2015;163:1–3. doi:10.7326/M15–0785.

 7. Forns X, Gordon SC, Zuckerman E, et al. Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent. J Hepatol. 2015;63:564–572.

 8. Kwo P, Gane E, Peng C-Y, et al. Efficacy and safety of grazoprevir/elbasvir +/- RBV for 12 or 16 weeks in patients with HCV G1 G4 or G6 infection who previously failed peginterferon/RBV: C-EDGE treatment-experienced. Poster presented at: The 50th International Liver Congress; April 22-26, 2015; Vienna, Austria. J Hepatol. 2015;62:S674.

 9. Roth D, Nelson DR, Bruchfeld A, et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. The Lancet, Vol. 386, Issue 10003, 1537–1545.

10. Rockstroh JK, et al. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. The Lancet HIV, Vol. 2, Issue 8, e319 - e327.